Q4 2023 13F Holders as of 31 Dec 2023
-
Type / Class
-
Equity / Common Stock, par value $0.00001 per share
-
Shares outstanding
-
108M
-
Number of holders
-
1
-
Total 13F shares, excl. options
-
18.2K
-
Shares change
-
-10.3K
-
Total reported value, excl. options
-
$19.1K
-
Value change
-
-$176K
-
Number of buys
-
1
-
Number of sells
-
-1
-
Price
-
$1.05
Significant Holders of Aclaris Therapeutics, Inc. - Common Stock, par value $0.00001 per share (ACRS) as of Q4 2023
2 filings reported holding ACRS - Aclaris Therapeutics, Inc. - Common Stock, par value $0.00001 per share as of Q4 2023.
Aclaris Therapeutics, Inc. - Common Stock, par value $0.00001 per share (ACRS) has 1 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 18.2K shares
of 108M outstanding shares and own 0.02% of the company stock.
Largest 10 shareholders include BlackRock Inc. (5.91M shares), CITADEL ADVISORS LLC (5.39M shares), VANGUARD GROUP INC (4.72M shares), Bain Capital Life Sciences Investors, LLC (3.5M shares), MILLENNIUM MANAGEMENT LLC (3.48M shares), Rock Springs Capital Management LP (3M shares), ACADIAN ASSET MANAGEMENT LLC (2.35M shares), D. E. Shaw & Co., Inc. (1.94M shares), Velan Capital Investment Management LP (1.76M shares), and TANG CAPITAL MANAGEMENT LLC (1.75M shares).
This table shows the top 1 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.